Form 4: Checkpoint Therapeutics CEO James Oliviero Reports Stock Transactions

James Oliviero, CEO of Checkpoint Therapeutics, reports the sale of shares to cover tax obligations and a transfer of shares to an irrevocable trust for his children.

Summary

• On February 28, 2024, James Oliviero, CEO of Checkpoint Therapeutics, reported the sale of 5,894 shares of common stock at an average price of $2.06 to cover tax obligations related to vesting restricted stock.
• Oliviero also transferred 9,056 shares of common stock to an irrevocable trust for the benefit of his minor children on the same day.
• Following these transactions, Oliviero directly owns 341,780 shares of Checkpoint Therapeutics common stock.
• The sale of shares to cover tax obligations was executed automatically according to company policy.
• Oliviero has no investment control over the shares held in the irrevocable trust.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates transactions by the CEO of Checkpoint Therapeutics.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the amounts are relatively small.

Key Dates